Evofem Biosciences (EVFM) Misses Q1 EPS by 7c

Evofem Biosciences (NASDAQ: EVFM) reported Q1 EPS of ($0.56), $0.07 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $1.63 million.

For earnings history and earnings-related data on Evofem Biosciences (EVFM) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Nike names former Pfizer CFO David Denton as new finance chief
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI